These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26099344)

  • 41. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.
    Lee MS; An SY; Jang GC; Kim DS
    Yonsei Med J; 2002 Aug; 43(4):527-32. PubMed ID: 12205742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
    Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
    Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S; Dong Y; Yin Y; Krucoff MW
    Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
    Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease.
    Wakiguchi H; Hasegawa S; Suzuki Y; Kudo K; Ichiyama T
    Pediatr Res; 2015 Apr; 77(4):536-40. PubMed ID: 25580740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in the treatment of Kawasaki disease.
    Dominguez SR; Anderson MS
    Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of circulating immune cells in acute Kawasaki disease suggests exposure to different antigens.
    Burns JC; Hsieh LE; Kumar J; Behnamfar N; Shimizu C; Sivilay N; Tremoulet AH; Franco A
    Clin Exp Immunol; 2020 Dec; 202(3):263-272. PubMed ID: 32812215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kawasaki disease.
    Kim DS
    Yonsei Med J; 2006 Dec; 47(6):759-72. PubMed ID: 17191303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methylprednisolone pulse therapy for massive lymphadenopathy in a child with intravenous immunoglobulin-resistant Kawasaki disease.
    Chen HH; Liu PM; Bong CN; Wu YT; Yang KD; Wang CL
    J Microbiol Immunol Infect; 2005 Apr; 38(2):149-52. PubMed ID: 15843862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A girl with extremely refractory Kawasaki disease: an instructive case with unusual course and outcome.
    Kossiva L; Karanassios E; Papadopoulos G; Karavanaki K
    Cardiol Young; 2012 Aug; 22(4):461-5. PubMed ID: 21933460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I; Prabhu SS
    Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.